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To the Editor:
Regarding the argument pre-
sented by Sculier et al.,1 predictive 
factors for determining which patients 
may benefit from adjuvant chemo-
therapy are important. Currently, the 
pathological stage based on tumor, 
node, metastasis (TNM) classification 
of surgical specimens is the only fac-
tor used. On the basis of the results of 
multiple randomized trials and meta-
analyses, patients treated according to 
the pathological stage are presumed 
to have better survival with adju-
vant chemotherapy than with surgery 
alone. Thus, to determine the setting 
in which adjuvant chemotherapy is 
applicable, TNM classification is 
used as a predictive factor. In addi-
tion to the pathological stage, some 
biological markers such as excision 
repair cross-complementing 12 are 
reported to be promising as predictive 
markers, but these are not yet used 
in clinical practice. In the manage-
ment of advanced lung cancer, bio-
logical markers such as mutation of 
epidermal growth factor receptor and 
translocation of echinoderm micro-
tubule-associated protein-like 4 gene 
and the anaplastic lymphoma kinase 
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We previously reported a case 
with epidermal growth factor receptor 
(EGFR)-mutant non–small-cell lung 
cancer where gefitinib rechallenge 
was effective after disappearance of 
T790M.1 “Temporal” T790M heteroge-
neity had been demonstrated in the pre-
vious report, whereas “spatial” T790M 
heterogeneity was also shown in the 
same patient.
After progression on gefi-
tinib rechallenge, he underwent 
pemetrexed with stable disease. Six 
months after gefitinib discontinua-
tion, rebiopsy was performed again. 
T790M mutation was still detected. 
He then received S-1, gemcitabine, 
and docetaxel, sequentially. A further 
6 months later, we repeated rebiopsy 
for both the primary tumor for which 
rebiospsy was done previously several 
times and a newly progressed pulmo-
nary metastasis. T790M was detected 
in the primary tumor, but not detected 
in the metastatic nodule. We then 
administered gefitinib again. Both the 
primary tumor and metastatic nod-
ules responded to gefitinib (Fig. 1). 
Gefitinib has been continued for 3 
months.
gene are used as predictive markers 
for the effectiveness of specific thera-
pies such as epidermal growth factor 
receptor tyrosine kinase inhibitor and 
anaplastic lymphoma kinase inhibitor 
therapies. Researchers and now clini-
cians each emphasize that predictive 
factors and prognostic factors have 
different meanings; a prognostic fac-
tor provides information on outcome, 
independent of the therapy that is 
used, whereas a predictive factor pro-
vides information on outcome with 
regard to a specific therapy.3
A concern that arises is that we 
also use TNM classification for the 
decision of lung cancer resection. In 
the setting of this decision, we do 
not use TNM classification as a pre-
dictive factor for treatment-specific 
outcome. Mountain, et al.4 stated that 
the purpose of staging was to classify 
patients according to the anatomi-
cal extent or biological severity of 
their disease. Numerous efforts have 
been made to determine how stag-
ing clearly differs from each other in 
TNM classification, the 7th revision 
of which accurately reflects the prog-
nosis of patients with lung cancer. 
A question arises as to whether the 
decision of lung cancer resection is 
justified on the basis of a prognostic 
factor. It may be necessary to reassess 
the usage of TNM classification as a 
predictive factor in the decision of 
lung cancer resection.
Hiroyuki Kaneda, MD, PhD
Yukihito Saito, MD, PhD, FCCP
Division of Thoracic Surgery,
Department of Thoracic and 
Cardiovascular Surgery,
Kansai Medical University, 
Osaka, Japan 
REFERENCES
 1. Sculier JP, Berghmans T, Meert AP. TNM 
classification and clinicopathological factors: 
what is helpful for adjuvant chemotherapy 
decision after lung cancer resection? J Thorac 
Oncol 2014;9:266–270.
 2. Olaussen KA, Dunant A, Fouret P, et al.; IALT 
Bio Investigators. DNA repair by ERCC1 
in non-small-cell lung cancer and cisplatin-
based adjuvant chemotherapy. N Engl J Med 
2006;355:983–991.
 3. Rossi A, Galetta D, Gridelli C. Biological 
prognostic and predictive factors in lung can-
cer. Oncology 2009;77(suppl 1):90–96.
 4. Mountain CF, Carr DT, Anderson WA. A 
system for the clinical staging of lung can-
cer. Am J Roentgenol Radium Ther Nucl Med 
1974;120:130–138.
LETTERS TO THE EDITOR
